NASDAQ:KYNB Kyntra Bio Q2 2026 Earnings Report $7.97 0.00 (0.00%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$7.92 -0.05 (-0.63%) As of 09/11/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileForecast Kyntra Bio EPS ResultsActual EPSN/AConsensus EPS -$3.18Beat/MissN/AOne Year Ago EPSN/AKyntra Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AKyntra Bio Announcement DetailsQuarterQ2 2026Date8/13/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesCompany Profile Kyntra Bio Earnings HeadlinesKyntra Bio (NASDAQ:KYNB) Earns "Buy" Rating from HC WainwrightSeptember 3, 2026 | americanbankingnews.comKyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 2, 2026 | globenewswire.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.September 13 at 1:00 AM | Base Camp Trading (Ad)Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing ObligationAugust 31, 2026 | globenewswire.comKyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call TranscriptAugust 14, 2026 | seekingalpha.comKyntra Bio: Q2 Earnings SnapshotAugust 13, 2026 | chron.comSee More Kyntra Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kyntra Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kyntra Bio and other key companies, straight to your email. Email Address About Kyntra BioFibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.View Kyntra Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsAmgen Drops 10% on a Trial It Didn't Even RunOil Above $100 Is Creating a New Opportunity Beyond the Major ProducersAST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing WindowAmerican Eagle Goes on Sale: Is It Time to Buy? Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
